Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates.
about
Emerging Threats in Antifungal-Resistant Fungal PathogensMechanisms of Candida biofilm drug resistanceCandida infections, causes, targets, and resistance mechanisms: traditional and alternative antifungal agentsMicafungin: an evidence-based review of its place in therapyHsp90 governs dispersion and drug resistance of fungal biofilmsAn automated high-throughput cell-based multiplexed flow cytometry assay to identify novel compounds to target Candida albicans virulence-related proteinsEchinocandin resistance: an emerging clinical problem?Metal Chelation as a Powerful Strategy to Probe Cellular Circuitry Governing Fungal Drug Resistance and MorphogenesisAntifungal Therapy: New Advances in the Understanding and Treatment of MycosisEpidemiology of invasive candidiasis: a persistent public health problemGenetic Basis of Antifungal Drug ResistanceDetermination of Echinocandin MICs for Candida species in less than 8 hours: comparison of the rapid susceptibility assay with the Clinical and Laboratory Standards Institute's broth microdilution assay.Modulation of Alternaria infectoria cell wall chitin and glucan synthesis by cell wall synthase inhibitors.Stimulation of chitin synthesis rescues Candida albicans from echinocandins.Functional analysis of Candida albicans GPI-anchored proteins: roles in cell wall integrity and caspofungin sensitivityAnidulafungin and voriconazole in invasive fungal disease: pharmacological data and their use in combination.Oropharyngeal candidiasis in the era of antiretroviral therapyPositions and numbers of FKS mutations in Candida albicans selectively influence in vitro and in vivo susceptibilities to echinocandin treatment.Novel FKS mutations associated with echinocandin resistance in Candida species.Mechanism of the synergistic effect of amiodarone and fluconazole in Candida albicansIn vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species.Engineering of New Pneumocandin Side-Chain Analogues from Glarea lozoyensis by Mutasynthesis and Evaluation of Their Antifungal Activity.Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcomeBreakthrough invasive candidiasis in patients on micafungin.Echinocandins: the newest class of antifungals.Target enzyme mutations confer differential echinocandin susceptibilities in Candida kefyrRole of FKS Mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance.Evaluating retinal toxicity of intravitreal caspofungin in the mouse eye.Regulatory circuitry governing fungal development, drug resistance, and disease.Differential Aspergillus lentulus echinocandin susceptibilities are Fksp independent.RNA sequencing revealed novel actors of the acquisition of drug resistance in Candida albicans.Elucidating drug resistance in human fungal pathogens.Overexpression of Candida albicans CDR1, CDR2, or MDR1 does not produce significant changes in echinocandin susceptibilityThe Celecoxib Derivative AR-12 Has Broad-Spectrum Antifungal Activity In Vitro and Improves the Activity of Fluconazole in a Murine Model of Cryptococcosis.Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase.A mutation in Tac1p, a transcription factor regulating CDR1 and CDR2, is coupled with loss of heterozygosity at chromosome 5 to mediate antifungal resistance in Candida albicansEmergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy.FKS2 mutations associated with decreased echinocandin susceptibility of Candida glabrata following anidulafungin therapy.Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia.Micafungin in the treatment of invasive candidiasis and invasive aspergillosis
P2860
Q26750816-A52B9CD7-0B09-4BF9-8BD5-75831B91AC25Q26827521-F9819340-192E-44C2-955D-40331E186EDCQ26863344-D9BEF83F-ECDE-4070-A356-D84B8B1B94BCQ27014780-8E29F8CA-ABE4-446C-9ED6-252FC9DF5969Q28476836-83F45086-C7F2-4703-AB84-E8093A79CC7FQ28544418-17D7E35D-B7D4-4929-957F-24BF265E405DQ28544739-A6C9B2E9-DD2E-4625-8678-E1277EDB35B8Q28554456-BCFA371A-C4EE-49E9-9B56-D3949CEE801BQ28818603-C9ADC3FF-0444-4D25-85AF-24E268BF1C2EQ29616758-C577999E-E5A5-4BF9-A433-8AD531B3D9EFQ30434904-67F9720D-D306-4ACB-8B6E-5B604827915CQ30435993-7E439E3D-1D3F-4D0C-9925-3DF64AB90C37Q30576509-8A850ED2-6721-4BD6-AEE8-48DB8EC6449AQ33326983-2C657C42-BB84-4DF1-805B-8B78C3D9D769Q33365853-5F2A89F8-B66C-463B-A930-76360A63D822Q33490772-DC7182D8-4218-412C-B0A8-84F1117FAB9DQ33746435-8E82EAAC-A09C-413A-B453-096371D84E69Q33798606-3DBEF349-82AA-4273-8810-2F61C3815A55Q33826330-669234C0-10B1-4DAF-A63F-B78C353D28CDQ33826488-DB39514A-1B54-4C46-AAB4-DA7575157C4AQ33876423-FA76CE62-FA3E-4F37-AB8F-12E97D334A13Q33886641-6DC29600-82B2-4095-B2A5-AA641C328467Q33935389-4D4F5D6D-B377-4AF5-916F-F29BFAC4885AQ33963538-1A4DB4E3-7BAB-48E1-8A2F-BDA0956F2006Q34019188-0B3A3220-558A-4370-99A2-C04D103A47BAQ34057480-63993911-0456-4D9F-A4B8-24BC848D66C8Q34058099-83006F6A-8A9F-4B76-8BB9-88E1F077851DQ34101326-200B7338-5581-499B-AC49-27CAEB4BE1A4Q34190284-599270E6-C79F-4AD9-A98E-FDEB729553C4Q34309395-16CAEB63-A4B2-4E7E-B401-5A68AEF3C33EQ34381656-60EA7813-F9C1-468A-A2D3-0DCD3831FDFCQ34419351-ADDFE8CE-467D-4A64-9B21-2794713BBA29Q34510707-4EB78A3B-AB30-4DCE-85A0-C64938988820Q34540684-560C0D17-287A-4A67-A724-E7FDEE6D9AE0Q34576400-A557CAC5-30D9-4947-A3D0-50FB994DE31DQ34588684-1E3AF2BD-3411-4C8C-8FB6-0AB4F5D5982EQ34721774-8440BC20-0212-4A63-8F26-05E6E8DD6676Q34737334-C7293E67-6B5B-48BC-86D1-CA923C8B890AQ34933267-CEB8E20B-AD55-41F9-89EA-E170788242E8Q35026516-DBC13564-9CB7-4AC5-87B1-0C951737310D
P2860
Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates.
description
2005 nî lūn-bûn
@nan
2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
name
Specific substitutions in the ...... clinical Candida sp. isolates.
@ast
Specific substitutions in the ...... clinical Candida sp. isolates.
@en
type
label
Specific substitutions in the ...... clinical Candida sp. isolates.
@ast
Specific substitutions in the ...... clinical Candida sp. isolates.
@en
prefLabel
Specific substitutions in the ...... clinical Candida sp. isolates.
@ast
Specific substitutions in the ...... clinical Candida sp. isolates.
@en
P2093
P2860
P1476
Specific substitutions in the ...... clinical Candida sp. isolates.
@en
P2093
A Flattery
C M Douglas
D S Perlin
E Register
J Nielsen Kahn
P2860
P304
P356
10.1128/AAC.49.8.3264-3273.2005
P407
P577
2005-08-01T00:00:00Z